Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Exlinkibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Exlinkibart overview

Exlinkibart (LVGN-6051) is under development for the treatment of advanced or metastatic malignancy including lung cancer, melanoma, recurrent head and neck cancer squamous cell carcinoma, B-cell non-Hodgkin’s lymphoma and non-small cell lung cancer, pancreatic cancer, gastrointestinal tract cancer and lymphoma. It is a humanized monoclonal antibody that acts by targeting CD137 and FCGR2B. It is administered through intravenous infusion. The drug candidate is developed based on cross-link antibody (xLinkAb) platform.

Lyvgen Biopharma overview

Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.

For a complete picture of Exlinkibart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.